An observational study in Ultrasound, Sarcopenia and Muscle Loss, sponsored by Universitatsmedizin Mainz - 1. Medizinische Klinik. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.
Sponsored by Universitatsmedizin Mainz - 1. Medizinische Klinik · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Sarcopenia with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Sarcopenia · Germany.
Among the 24 studies in Sarcopenia with a site in Germany, this one has the largest enrollment of the 11 observational ones that give a count, is one of 5 that started in 2020, is one of 11 observational ones, and was the 20th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →6 of the 24 studies in Sarcopenia with a site in Germany are open now. Recruiting first, the newest first:
University Hospital, Bonn · Sites in Germany
Ages 65+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 70+
Charite University, Berlin, Germany · Sites in Germany
Ages 45–75
Universitatsmedizin Mainz - 1. Medizinische Klinik · Sites in Germany
Ages 18+
University Hospital, Bonn · Sites in Germany, Italy
Ages 18–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2020.
This study's enrollment of 900 is above the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 94 across the 13 interventional studies, 175 across the 11 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 24 have an industry lead sponsor. The 10 most frequent:
Universitatsmedizin Mainz - 1. Medizinische Klinik is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Universitatsmedizin Mainz - 1. Medizinische Klinik has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
2 of the studies in Sarcopenia with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07291765University Hospital, BonnBlood Flow Restriction Training in Acute Geriatric Rehabilitation | 2026-12-31 |
| NCT06889545Universitätsklinikum Hamburg-EppendorfComparison of Preoperative Frailty Assessment Tools | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Sarcopenia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Frailty or debility is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a component of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but require further validation.
The aim of this project is to be able to estimate the prognosis of patients at an early stage by measuring sarcopenia using sonography.
Frailty is a well-known syndrome that has a negative impact on many diseases and the course of disease. Patients affected by frailty are particularly vulnerable due to their inadequate ability to deal with extrinsic and intrinsic stress factors. The prevalence of frailty increases with age, affecting 15% of people over the age of 65 and 25% of people over the age of 80.
Frailty is the end result of an interplay between malnutrition, cognitive impairment and muscle wasting. Each of these factors can be further examined and measured, but they also influence each other. In particular, reduced muscle mass and muscle function have been associated with poor quality of life and a worse course of disease. Sarcopenia is therefore becoming an increasingly important factor in various disease patterns and should be monitored further. Muscle wasting and sarcopenia have multifactorial causes. Physical inactivity, chronic inflammation associated with chronic diseases, and malnutrition are particularly noteworthy in this context. Cross-sectional measurement of several muscles at the level of the lumbar vertebrae (L3), normalized to body size, and dual-energy X-ray absorptiometry are currently the most commonly used techniques for measuring sarcopenia. However, the measurements require complex equipment and procedures. In addition, radiological imaging is costly and causes radiation exposure. Therefore, attempts have been made in the past to simplify the measurements. Sonographic measurement is a practical alternative. Many different muscle groups are accessible to ultrasound. In particular, the thigh muscles and the psoas major muscle can be easily visualized sonographically. The sonographic assessment of the psoas muscle area index (PMAI) and the thigh muscle thickness index (TMTI) are approaches for bedside morphometry that the investigators use primarily.
Sarcopenia needs to be further investigated and included in the evaluation of therapeutic concepts. Recently, Zhang et al. showed that radiologically measured reduced psoas muscle mass was associated with poorer overall survival in HCC patients. Furthermore, it has been suggested several times that sarcopenia should be integrated into the MELD classification for liver transplantation. The investigators were also recently able to show in a cohort of COVID-19 patients that reduced muscle mass was associated with a poorer disease course during the pandemic.
The investigators expect sonographic measurements of the musculature to provide a better assessment of prognosis, quality of life and functional results under therapy.
The study population consists of patients treated at the First Medical Clinic of the University Medical Center in Mainz who are scheduled to undergo a planned ultrasound examination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who receive a standard ultrasound also get a measurement of the musculature.
Diagnostic Test: Ultrasound
The thickness of the psoas muscle and the musculus quadriceps femoris will be measured by ultrasound
Complication
Number of participants with decompensation of the underlying disease (e.g. liver cirrhosis: hydropic decompensation) or death
Time frame: From date of inclusion until the date of first documented decompensation or death from any cause, whichever came first, assessed up to two years
Plan to share: Undecided — The data will be published as part of publications if necessary.
Ran from Oct 2020 to primary completion in May 2022, 19 months.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's 19 months is below that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitatsmedizin Mainz - 1. Medizinische Klinik